HPV Vaccines Raise International Red Flags
The debate has always been hot about the risk-benefit ratio of human papillomavirus (HPV) vaccines, ever since Merck’s Gardasil-4 vaccine was fast tracked to licensure by the U.S. Food and Drug Administration (FDA) in 2006 followed by persistent reports of young girls suffering serious health problems after vaccination. Now, new international investigations and reports of failure are hitting the headlines, prompting additional worries about severe reactions to HPV vaccines. Three HPV vaccines are available both in the United States and the European Union. Merck and…